Precision Medicine Enablement via Advanced Diagnostics Workgroup

Precision Medicine Enablement via Advanced Diagnostics

• Fully integrate PGx services into the pharmaceutical care process to support useful clinical decision making through increased availability of data.
• Ensure providers and payors have secure and timely access to the information necessary to identify patients who have not achieved clinical goals of therapy.
• Optimize testing usefulness and interpretation by strengthening the relationship between the FDA and laboratories that provide PGx testing.
• Promote precision medicine literacy among providers and patients in the context of its application to the clinical care role in optimizing medication use.
• Enable evidence-based processes and strategies that support precision medicine as a tool used in the CMM process and enable effective standardization, awareness and interpretation.

Workgroup Co-Lead

Co-Lead: Brian Caveney, MD, JD, MPH, President, Enterprise-Wide Chief Medical Officer, LabCorp

Workgroup Co-Lead

Co-Lead: Jill Bates, PharmD, MS, BCOP, FASHP, PHASER Pharmacy Program Manager, Durham VA Health Care System; Associate Professor of Clinical Education, UNC Eshelman School of Pharmacy

Workgroup Participants

• Marcia Eisenberg, PhD, Chief Scientific Officer, Senior Vice President, LabCorp
• Steve Anderson, PhD, Chief Scientific Officer-Covance, Senior Vice President, LabCorp
• Tom Kraus, JD, MHS, Vice President, Office of Government Relations, American Society of Health-System Pharmacists
• Jacques Turgeon, BPharm, PhD, Chief Scientific Officer, Tabula Rasa; CEO, Precision Pharmacotherapy Research and Development Institute
• Dorothy (Dot) Adcock, MD, Chief Medical Officer and Senior Vice President, LabCorp
• Anthony Morreale, PharmD, MBA, BCPS, FASHP, Associate Chief Consultant for Clinical Pharmacy Services & Policy, Pharmacy Benefits Management VACO
• Chet Robson, DO, MHCDS, FAAFP, Medical Director, Walgreens Co.
• Philip Empey, PharmD, PhD, Director, PGx Center of Excellence; Associate Director, Institute for Precision Medicine; Associate Professor, Dept. of Pharmacy and Therapeutics, Center for Clinical Pharmaceutical Sciences
  and the Clinical and Translational Science Institute
• Jane Gilbert, CPA, Director, Retiree Health Care, Kentucky Teachers’ Retirement System
• Sarah Mallak, PharmD, Director, Clinical Product Design & Strategy, Genoa Healthcare
• Julie Ceno-England, MD, Interim Chief Medical Officer, OneOme
• Amber Cipriani, PharmD, BCOP, CPP, Precision Medicine Pharmacy Coordinator, UNC Medical Center; Clinical Assistant Professor, UNC Eshelman School of Pharmacy
• Cyrine-Eliana Haidar, Pharm.D., BCPS, BCOP, Clinical Pharmacogenetics Coordinator, St. Jude Children’s Research Hospital

Areas of Further Work

1. Regulation: Strengthen the relationship of the FDA with laboratories that provide pharmacogenomic testing to optimize its usefulness to patients and providers
2. HIT and AI: Develop tools that enable the practice of precision medicine and advanced diagnostics?
3. Marketplace Strategy: Create and implement a plan that promotes precision medicine literacy and application to clinical care
4. Education and Public Awareness: Standardize a process for precision medicine care and support providers in its delivery and adoption
5. Evidence-Based Process: Create an evidence-based process that supports precision medicine data and enables effective understanding, awareness and interpretation

Standing Date:

• Every other Friday from 11:30-12:30 pm EST
• 2019: 7/24, 8/13, 8/30, 9/13, 9/27, 10/11, 10/25, 11/8, 11/22, 12/6, 12/20
• 2020: 1/13, 1/24, 2/21, 3/6, 4/3, 4/17, 5/1, 5/15, 5/29, 6/12, 6/26, 7/10, 7/24, 8/7, 8/21, 9/4, 9/18, 10/2, 10/16, 10/30, 11/13, 11/27, 12/11

If interested in learning more about the Workgroup, contact:

• Izzy Serji, Operations Manager, GTMRx, E: [email protected]